Aurobindo Pharma Q2 FY27 Results (NSE: AUROPHARMA)

· Analysis by Alpha Inflection

Signal: Growth reaccelerated

Aurobindo Pharma Q2 FY27 key financials
MetricValueYoYQoQ
Revenue₹10,263.29 Cr+23.8%+12.2%
EBIT₹1,618.72 Cr+29.6%
Net profit₹1,123.84 Cr+32.5%
EPS₹19.57+34.0%
EBIT margin20.9%

P&L walk

Consolidated revenue increased to ₹102632.9 million, +23.8% YoY and +12.2% QoQ, while EBITDA margin expanded to 20.9% from 20.3% YoY; PAT rose 32.5% to ₹11238.4 million, helped by operating profit growth and subsidiary scale.

View original filing

Research and educational content only. Not investment advice.